A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
This is a Phase Ib multicenter, open-label study of JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy, targeting both cluster of differentiation (CD) CD19 and CD20 for the treatment of adult participants with B-Cell non-Hodgkin lymphoma (B-NHL).
Lymphoma, Non-Hodgkin|Lymphoma, B-Cell
BIOLOGICAL: JNJ-90014496
Occurrence of Adverse Events (AEs) [Safety and Tolerability], Occurrence of any AEs, including dose limiting toxicities (DLTs)., Up to 24 months|Determination of the Recommended Phase 2 Dose (RP2D) of JNJ-90014496 in Participants with B-cell non-Hodgkin lymphoma (B-NHL), Based on the assessment of DLTs rates and overall safety profile., Up to 24 months
Overall Response (OR), Complete response (CR) and partial response (PR) will be assessed by Lugano 2014 guidelines., Up to 24 months|Time to Response (TTR), The time from the date of JNJ-90014496 infusion to the first documented CR or PR will be assessed by Lugano 2014 guidelines., Up to 24 months|Duration of Response (DOR), The time from the first documented CR or PR to relapse or death, whichever occurs first will be assessed by Lugano 2014 guidelines., Up to 24 months|Pharmacokinetic Evaluation of JNJ-90014496, JNJ-90014496 blood levels will be reported., Up to 24 months
This is a Phase Ib multicenter, open-label study of JNJ-90014496, an autologous bi-specific chimeric antigen receptor (CAR) T-cell therapy, targeting both cluster of differentiation (CD) CD19 and CD20 for the treatment of adult participants with B-Cell non-Hodgkin lymphoma (B-NHL).